Adlai NortyeANL -1.57% Altman Z-Score is -13.49 as of Jun. 28, 2026. The stock has 7 warning signs investors should review. Among 934 Biotechnology companies, Adlai Nortye ranks worse than 89.29% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of -13.49 is in distress zone. This implies bankruptcy possibility in the next two years.
Adlai Nortye has a Altman Z-Score of -13.49, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Adlai Nortye's Altman Z-Score or its related term are showing as below:
ANL'
s Altman Z-Score Range Over the Past 10 Years
Min: -21.73 Med: -21.73 Max: -13.49
Current: -13.49
During the past 5 years, Adlai Nortye's highest Altman Z-Score was -13.49. The lowest was -21.73. And the median was -21.73.
Adlai Nortye (NAS:ANL) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Adlai Nortye Altman Z-Score Related Terms
Adlai Nortye Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANL vs PHAT, AURA, RLMD: Altman Z-Score Comparison
For the Biotechnology subindustry, Adlai Nortye's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Adlai Nortye's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
-0.428
+
1.4
*
-13.5
+
3.3
*
-0.9886
+
0.6
*
15.0621
+
1.0
*
0.1452
=
-13.49
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Adlai Nortye (ANL) has a Altman Z-Score of -13.49 as of Jun. 28, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #834 out of 934 companies in the Biotechnology industry, placing it in the top 89.3%.
Is Adlai Nortye's Altman Z-Score too high?
Adlai Nortye's current Altman Z-Score is -13.49. Based on the distribution chart, Adlai Nortye ranks #834 out of 934 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's Altman Z-Score compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #834 out of 934 companies for Altman Z-Score. This places Adlai Nortye in the lower half of its industry. The industry median Altman Z-Score is 2.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.63, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current Altman Z-Score is -13.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Altman Z-Score of -13.49. The current Altman Z-Score is -13.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Altman Z-Score is -13.49 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 